NASDAQ:VSTM Verastem Q4 2024 Earnings Results & Report $7.71 +0.26 (+3.49%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$8.20 +0.49 (+6.29%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Verastem missed analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$1.33 versus the -$0.76 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 20, 2025TimeBefore Market OpensConference Call DateMarch 19, 2025Conference Call7:00 PM ET Verastem EPS ResultsActual EPS-$1.33Consensus EPS -$0.76Beat/MissMissed by -$0.57One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersVerastem Revenue ResultsActual RevenueN/AExpected Revenue$0.15 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsVerastem's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Verastem Q4 2024 Earnings FAQ Did Verastem beat earnings estimates for Q4 2024? Verastem (NASDAQ:VSTM) reported earnings of -$1.33 per share for Q4 2024, missing the consensus estimate of -$0.76. The report was announced on Thursday, March 20, 2025. When is Verastem's next earnings date? Verastem's next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Verastem on the company's earnings history page. Verastem Earnings HeadlinesVerastem Oncology's investigational drug delivers encouraging responses across multiple cancersOctober 14 at 10:40 PM | msn.comVerastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers TranscriptOctober 14 at 8:00 PM | seekingalpha.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 15 at 1:00 AM | The Oxford Club (Ad)Verastem Announces $234 Million Oncology Financing TransactionOctober 14 at 6:11 PM | tipranks.comVS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two ...October 14 at 12:38 PM | uk.finance.yahoo.comVerastem Oncology Names Michael Bailey CEO; Prices $250 Million Offering -- Shares Rise Pre-BellOctober 14 at 12:38 PM | finance.yahoo.comSee More Verastem Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email. Email Address About VerastemVerastem (NASDAQ:VSTM) Oncology (NASDAQ:VSTM) is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancers driven by abnormalities in the RAS/MAPK signaling pathway. The company’s research is aimed at addressing cancers with limited treatment options, including ovarian cancer and other solid tumors. Verastem’s lead product, avutometinib, is a treatment targeting the RAF/MEK signaling pathway and is marketed in the United States under the brand name Avmapki for certain patients with recurrent low-grade serous ovarian cancer. The company has also developed defactinib, an investigational focal adhesion kinase inhibitor being evaluated in combination with avutometinib and other therapies for selected cancers. Founded in 2010, Verastem is headquartered in Needham, Massachusetts. Its operations and clinical development activities have included collaborations and trials involving medical institutions and patients in the United States and other international markets. Dan Paterson serves as the company’s president and chief executive officer.View Verastem ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
